High-dose fast infusion of parenteral iron isomaltoside is efficacious in inflammatory bowel disease patients with iron-deficiency anaemia without profound changes in phosphate or fibroblast growth factor 23

European Consensus on the Diagnosis and Management of Iron Deficiency and Anaemia in Inflammatory Bowel Diseases

(2015) Axel U Dignass et al.   Journal of Crohns & Colitis

A randomized, open-label trial of iron isomaltoside 1000 (Monofer®) compared with iron sucrose (Venofer®) as maintenance therapy in haemodialysis patients

(2015) Sunil Bhandari et al.   NEPHROLOGY DIALYSIS TRANSPLANTATION

A randomized trial of iron isomaltoside 1000 versus oral iron in non-dialysis-dependent chronic kidney disease patients with anaemia

(2015) Philip A. Kalra et al.   NEPHROLOGY DIALYSIS TRANSPLANTATION

A 1-year trial of repeated high-dose intravenous iron isomaltoside 1000 to maintain stable hemoglobin levels in inflammatory bowel disease

(2015) Walter Reinisch et al.   SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY

Intravenous iron isomaltoside 1000 (Monofer®) reduces postoperative anaemia in preoperatively non-anaemic patients undergoing elective or subacute coronary artery bypass graft, valve replacement or a combination thereof: a randomized double-blind placebo-

(2015) P. I. Johansson et al.   VOX SANGUINIS

A Randomized, Open-Label, Non-Inferiority Study of Intravenous Iron Isomaltoside 1,000 (Monofer) Compared With Oral Iron for Treatment of Anemia in IBD (PROCEED)

(2013) Walter Reinisch et al.   AMERICAN JOURNAL OF GASTROENTEROLOGY

Effects of iron deficiency anemia and its treatment on fibroblast growth factor 23 and phosphate homeostasis in women

(2013) Myles Wolf et al.   JOURNAL OF BONE AND MINERAL RESEARCH

Iron isomaltoside 1000: a new intravenous iron for treating iron deficiency in chronic kidney disease

(2011) Björn Wikström et al.   JOURNAL OF NEPHROLOGY

Iron deficiency drives an autosomal dominant hypophosphatemic rickets (ADHR) phenotype in fibroblast growth factor-23 (Fgf23) knock-in mice

(2011) E. G. Farrow et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

When is high-dose intravenous iron repletion needed? Assessing new treatment options

(2011) Gozzard   Drug Design Development and Therapy

The health care cost of intravenous iron treatment in IBD patients depends on the economic evaluation perspective

(2010) Palle Bager et al.   Journal of Crohns & Colitis

GERD and insomnia—first degree relatives or distant cousins?

(2010) Ellen Stein et al.   Nature Reviews Gastroenterology & Hepatology

Hypophosphatemia induced by intravenous administration of saccharated ferric oxide

(2009) Yuichiro Shimizu et al.   BONE

Oral and intravenous iron treatment in inflammatory bowel disease: Hematological response and quality of life improvement

(2009) Javier P. Gisbert et al.   INFLAMMATORY BOWEL DISEASES

FGF23 Elevation and Hypophosphatemia after Intravenous Iron Polymaltose: A Prospective Study

(2009) Belinda J. Schouten et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

Anemia and inflammatory bowel diseases

(2009) Fernando Gomollón et al.   WORLD JOURNAL OF GASTROENTEROLOGY